Annovis Bio, Inc.

Frontrunner in advancing a safe, once-daily pill to treat neurodegeneration

NYSE: ANVS

Annovis is recognized as an innovative player in neurodegenerative medicine, grounded in decades of foundational research, guided by a leadership team deeply rooted in neuroscience, and driven by a pipeline designed to address the massive unmet need in Alzheimer's, Parkinson's, and other neurological disorders. The company stands out due to a validated mechanism of action, FDA engagement, multiple clinical programs, insider buying from leadership, and strong momentum metrics.

Buntanetap - lead drug candidate

Buntanetap is a once-a-day pill that readily enters the brain and inhibits the translation of neurotoxic aggregating proteins, including APP/Aβ, tau, aSYN, TDP-43, huntingtin, and prion protein. It does so by strengthening the binding of mRNA, coding for these proteins, to IRP1 and preventing their translation by the ribosome. Lowering levels of neurotoxic proteins impedes the toxic cascade and restores axonal transport to normal speed, improves synaptic transmission, reverses inflammation, and prevents induction of cell death, thereby improving cognitive and motor impairments.

Momentum That Defies Market Volatility



- Annovis has shown its drug buntanetap works in early AD in Phase 2/3 trial.
- The FDA has given clear guidance: replicating these results in a larger population will allow to file for New Drug Application (NDA).
- The pivotal Phase 3 trial is approaching full enrollment with pivotal data expected in late 2026.

If Annovis' study succeeds, the implications for buntanetap extend well beyond Alzheimer's disease, representing a massive opportunity to change the treatment landscape for cognitive decline.

Comparison with approved drugs

- Current standard-of-care medications (i.e. Aricept) provide only temporary symptomatic relief, with benefits typically diminishing after six months.
- Recently approved disease-modifying treatments (Leqembi, Kisunla) slow cognitive decline by approximately 35% but do not improve cognition.



Buntanetap has demonstrated symptomatic improvements beyond the standard-of-care and holds the potential for disease modification, which is being evaluated in the ongoing pivotal Phase 3 study.

Safety

13 completed clinical trials

> 1,200 patients treated

0 drug-related serious adverse events

SAFE even at doses 8x higher than effective dose

ApoE4 carriers show no side effects

Symptomatic efficacy



- Buntanetap significantly improves cognition across four studies in Alzheimer's and Parkinson's diseases.
- Buntanetap shows a unified and reproducible treatment pattern: profound cognitive benefit in patients with mild dementia (MMSE >20) and biomarker-confirmed presence of amyloid and tau.

Target patient group



Disease-modifying efficacy

Buntanetap shows reduction in key plasma biomarkers after 3 months of treatment in early AD patients.



Contact

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

+1 (484) 875-3192
info@annovisbio.com

@annovisbio
Annovis Bio, Inc.